Bleeding Disorders
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Journal Pre-Proof
Journal Pre-proof Society for Maternal-Fetal Medicine (SMFM) Consult Series #56: Hepatitis C in Pregnancy: Updated Guidelines Society for Maternal-Fetal Medicine (SMFM), Sarah K. Dotters-Katz, MD MMHPE, Jeffrey A. Kuller, MD, Brenna L. Hughes, MD, MSc PII: S0002-9378(21)00639-6 DOI: https://doi.org/10.1016/j.ajog.2021.06.008 Reference: YMOB 13905 To appear in: American Journal of Obstetrics and Gynecology Please cite this article as: Society for Maternal-Fetal Medicine (SMFM), Dotters-Katz SK, Kuller JA, Hughes BL, Society for Maternal-Fetal Medicine (SMFM) Consult Series #56: Hepatitis C in Pregnancy: Updated Guidelines, American Journal of Obstetrics and Gynecology (2021), doi: https:// doi.org/10.1016/j.ajog.2021.06.008. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier Inc. 1 Society for Maternal-Fetal Medicine (SMFM) Consult Series #56: Hepatitis C in 2 Pregnancy: Updated Guidelines 3 4 Society for Maternal-Fetal Medicine (SMFM); Sarah K. Dotters-Katz, MD MMHPE; Jeffrey A. 5 Kuller, MD; Brenna L. Hughes, MD, MSc 6 7 (Replaces Consult #43, November 2017) 8 9 10 Address all correspondence to: 11 The Society for Maternal-Fetal Medicine: Publications Committee 12 409 12th St, SW 13 Washington, DC 20024 14 Phone: 202-863-2476 15 Fax: 202-554-1132 16 Email: [email protected] Journal Pre-proof 17 18 Reprints will not be available 19 20 Condensation: This Consult reviews the current literature on hepatitis C in pregnancy and 21 provides recommendations based on the available evidence. -
The Rare Coagulation Disorders
Treatment OF HEMOPHILIA April 2006 · No. 39 THE RARE COAGULATION DISORDERS Paula HB Bolton-Maggs Department of Haematology Manchester Royal Infirmary Manchester, United Kingdom Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2006 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s web site at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff. -
SUBGALEAL HEMATOMA Sarah Meyers MS4 Ilse Castro-Aragon MD CASE HISTORY
SUBGALEAL HEMATOMA Sarah Meyers MS4 Ilse Castro-Aragon MD CASE HISTORY Ex-FT (37w6d) male infant born by low transverse C-section for arrest of descent and chorioamnionitis to a 34-year-old G2P1 mother. The infant had 1- and 5-minute APGAR scores of 9 and 9, weighed 3.625 kg (54th %ile), and had a head circumference of 34.5 cm (30th %ile). Following a challenging delivery of the head during C/s, the infant was noted to have left-sided parietal and occipital bogginess, and an ultrasound was ordered due to concern for subgaleal hematoma. PEDIATRIC HEAD ULTRASOUND: SUBGALEAL HEMATOMA Superficial pediatric head ultrasound showing moderately echogenic fluid collection (green arrow), superficial to the periosteum (blue arrow), crossing the sagittal suture (red arrow). Findings on U/S consistent with large parieto-occipital subgaleal hematoma. PEDIATRIC HEAD ULTRASOUND: SUBGALEAL HEMATOMA Superficial pediatric head ultrasound showing moderately echogenic fluid collection (green arrow), consistent with large parieto-occipital subgaleal hematoma. CLINICAL FOLLOW UP - Subgaleal hematoma was confirmed on ultrasound and the infant was transferred from the newborn nursery to the NICU for close monitoring, including hourly head circumferences and repeat hematocrit measurements - Serial head circumferences remained stable around 34 cm and hematocrit remained stable between 39 and 41 throughout hospital course - The infant was subsequently treated with phototherapy for hyperbilirubinemia, thought to be secondary to resorption of the SGH IN A NUTSHELL: -
Swollen Scalp (Caput Succedaneum and Cephalohematoma) N
n Swollen Scalp (Caput Succedaneum and Cephalohematoma) n What are some possible Some babies are born with swelling or a large bump on the scalp. Caput succedaneum is complications of swollen sculp? swelling under the skin of the scalp, while cepha- With caput succedaneum, complications are rare. lohematoma results from bleeding under the With cephalohematoma, complications occur occasion- scalp. Both conditions are related to pressure on ally: the baby’s head during birth. They are usually harmless. Skull fracture may occur. These fractures usually heal without problems. If the collection of blood is large, it may result in anemia (low hemoglobin). What are caput succedaneum and Large cephalohematomas may result in jaundice. This is cephalohematoma, and what do a yellow color of the skin caused by excess bilirubin, a they look like? substance produced by breakdown of blood as the cepha- lohematoma is resolving. Caput succedaneum. More serious complications, such as bleeding into the Swelling (edema) of the scalp. The swelling is caused by brain or injury to the brain from skull fracture, occur only pressure on the head during delivery. Sometimes there is rarely. bruising, but the swelling is not from blood in the scalp. Occasionally, calcium deposits develop in the area of the There may be swelling and bruising of the face, if your cephalohematoma. This may leave a hard bump that lasts baby was born face first. for several months. Swelling goes down after a few days. When it does, you may notice “molding,” a pointed appearance of your baby’s head that wasn’t obvious before. -
ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4
ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4 ISTH 2012 11.6.2012 14:46 Page 1 Table of Contents 3 Welcome Message from the Meeting President 3 Welcome Message from ISTH Council Chairman 4 Welcome Message from SSC Chairman 5 Committees 7 ISTH Future Meetings Calendar 8 Meeting Sponsors 9 Awards and Grants 2012 12 General Information 20 Programme at a Glance 21 Day by Day Scientific Schedule & Programme 22 Detailed Programme Tuesday, 26 June 2012 25 Detailed Programme Wednesday, 27 June 2012 33 Detailed Programme Thursday, 28 June 2012 44 Detailed Programme Friday, 29 June 2012 56 Detailed Programme Saturday, 30 June 2012 68 Hot Topics Schedule 71 ePoster Sessions 97 Sponsor & Exhibitor Profiles 110 Exhibition Floor Plan 111 Congress Centre Floor Plan www.isth.org ISTH 2012 11.6.2012 14:46 Page 2 ISTH 2012 11.6.2012 14:46 Page 3 WelcomeCommittees Messages Message from the ISTH SSC 2012 Message from the ISTH Meeting President Chairman of Council Messages Dear Colleagues and Friends, Dear Colleagues and Friends, We warmly welcome you to the elcome It is my distinct privilege to welcome W Scientific and Standardization Com- you to Liverpool for our 2012 SSC mittee (SSC) meeting of the Inter- meeting. national Society on Thrombosis and Dr. Cheng-Hock Toh and his col- Haemostasis (ISTH) at Liverpool’s leagues have set up a great Pro- UNESCO World Heritage Centre waterfront! gramme aiming at making our off-congress year As setting standards is fundamental to all quality meeting especially attractive for our participants. -
Whole-Exome Sequencing of a Patient with Severe and Complex Hemostatic Abnormalities Reveals a Possible Contributing Frameshift Mutation in C3AR1
Downloaded from molecularcasestudies.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Whole-exome sequencing of a patient with severe and complex hemostatic abnormalities reveals a possible contributing frameshift mutation in C3AR1 Eva Leinøe1, Ove Juul Nielsen1, Lars Jønson2 and Maria Rossing2∗ Department of Hematology1 and Center for Genomic Medicine2, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark Running head: WES reveals a C3AR1 mutation in a complex hemostatic patient ∗Corresponding author: Maria Rossing Center for Genomic Medicine Rigshospitalet University of Copenhagen Blegdamsvej 9 DK-2100 Copenhagen Denmark E-mail: [email protected] Phone: +45 3545 3016 Fax: +45 3545 4435 1 Downloaded from molecularcasestudies.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract The increasing availability of genome-wide analysis has made it possible to rapidly sequence the exome of patients with undiagnosed or unresolved medical conditions. Here, we present the case of a 64-year-old male patient with schistocytes in the peripheral blood smear and a complex and life-threatening coagulation disorder causing recurrent venous thromboembolic events, severe thrombocytopenia, and subdural hematomas. Whole-exome sequencing revealed a frameshift mutation (C3AR1 c.355-356dup, p.Asp119Alafs*19) resulting in a premature stop in C3AR1 (Complement Component 3a Receptor 1). Based on this finding, atypical hemolytic uremic syndrome was suspected due to a genetic predisposition, and a targeted treatment regime with Eculizumab was initiated. Life-threatening hemostatic abnormalities would most likely have persisted had it not been for the implementation of whole-exome sequencing in this particular clinical setting. -
Diagnosis of Hemophilia and Other Bleeding Disorders
Diagnosis of Hemophilia and Other Bleeding Disorders A LABORATORY MANUAL Second Edition Steve Kitchen Angus McCraw Marión Echenagucia Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2010 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. For permission to reproduce or translate this document, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s website at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel.: (514) 875-7944 Fax: (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org Diagnosis of Hemophilia and Other Bleeding Disorders A LABORATORY MANUAL Second Edition (2010) Steve Kitchen Angus McCraw Marión Echenagucia WFH Laboratory WFH Laboratory (co-author, Automation) Training Specialist Training Specialist Banco Municipal Sheffield Haemophilia Katharine Dormandy de Sangre del D.C. and Thrombosis Centre Haemophilia Centre Universidad Central Royal Hallamshire and Thrombosis Unit de Venezuela Hospital The Royal Free Hospital Caracas, Venezuela Sheffield, U.K. London, U.K. on behalf of The WFH Laboratory Sciences Committee Chair (2010): Steve Kitchen, Sheffield, U.K. Deputy Chair: Sukesh Nair, Vellore, India This edition was reviewed by the following, who at the time of writing were members of the World Federation of Hemophilia Laboratory Sciences Committee: Mansoor Ahmed Clarence Lam Norma de Bosch Sukesh Nair Ampaiwan Chuansumrit Alison Street Marión Echenagucia Alok Srivastava Andreas Hillarp Some sections were also reviewed by members of the World Federation of Hemophilia von Willebrand Disease and Rare Bleeding Disorders Committee. -
Approach to Bleeding Diathesi
Approach to Bleeding Diathesis Dr.Nalini K Pati MD, DNB, DCH (Syd), FRCPA Paediatric Haematologist Royal Children’s Hospital Melbourne Australia Objectives Objectives - I I. Clinical aspects of bleeding Clinical aspects of bleeding II. Hematologic disorders causing bleeding • Coagulation factor disorders • Platelet disorders III. Approach to acquired bleeding disorders • Hemostasis in liver disease • Surgical patients • Warfarin toxicity IV. Approach to laboratory abnormalities • Diagnosis and management of thrombocytopenia V. Drugs and blood products used for bleeding Clinical Features of Bleeding Disorders Petechiae Platelet Coagulation (typical of platelet disorders) disorders factor disorders Site of bleeding Skin Deep in soft tissues Mucous membranes (joints, muscles) (epistaxis, gum, vaginal, GI tract) Petechiae Yes No Ecchymoses (“bruises”) Small, superficial Large, deep Hemarthrosis / muscle bleeding Extremely rare Common Do not blanch with pressure Bleeding after cuts & scratches Yes No (cf. angiomas) Bleeding after surgery or trauma Immediate, Delayed (1-2 days), usually mild often severe Not palpable (cf. vasculitis) Ecchymoses (typical of coagulation factor disorders) Objectives - II Hematologic disorders causing bleeding – Coagulation factor disorders – Platelet disorders Coagulation factor disorders Hemophilia A and B Inherited bleeding Acquired bleeding Hemophilia A Hemophilia B disorders disorders Coagulation factor deficiency Factor VIII Factor IX – Hemophilia A and B – Liver disease – vonWillebrands disease – Vitamin K Inheritance X-linked X-linked recessive recessive – Other factor deficiencies deficiency/warfarin overdose Incidence 1/10,000 males 1/50,000 males –DIC Severity Related to factor level <1% - Severe - spontaneous bleeding 1-5% - Moderate - bleeding with mild injury 5-25% - Mild - bleeding with surgery or trauma Complications Soft tissue bleeding Hemarthrosis (acute) Hemophilia Clinical manifestations (hemophilia A & B are indistinguishable) Hemarthrosis (most common) Fixed joints Soft tissue hematomas (e. -
Dysfibrinogenemia and Thrombosis
Dys®brinogenemia and Thrombosis Timothy Hayes, DVM, MD c Objectives.ÐTo review the state of the art relating to sus of experts attending the conference was reached. The congenital dys®brinogenemia as a potential risk factor for results of the discussion were used to revise the manuscript thrombosis, as re¯ected by the medical literature and the into its ®nal form. consensus opinion of recognized experts in the ®eld, and Conclusions.ÐConsensus was reached on 5 conclusions to make recommendations for the use of laboratory assays and 2 recommendations concerning the use of testing for for assessing this thrombotic risk in individual patients. dys®brinogens in the assessment of thrombotic risk in in- Data Sources.ÐReview of the medical literature, pri- dividual patients. Detailed discussion of the rationale for marily from the last 10 years. each of these recommendations is found in the text of this Data Extraction and Synthesis.ÐAfter an initial assess- article. Compared with the other, more common heredi- ment of the literature, key points were identi®ed. Experts tary thrombophilias, dys®brinogenemia encompasses a di- were assigned to do an in-depth review of the literature verse group of defects with varied clinical expressions. and to prepare a summary of their ®ndings and recom- Congenital dys®brinogenemia is a relatively rare cause of mendations. A draft manuscript was prepared and circu- thrombophilia. Therefore, routine testing for this disorder lated to every participant in the College of American Pa- is not recommended as part of the laboratory evaluation thologists Conference on Diagnostic Issues in Thrombo- of a thrombophilic patient. -
Platelet Function Disorders
TREATMENT OF HEMOPHILIA APRIL 2008 • NO 19 PLATELET FUNCTION DISORDERS Second Edition Anjali A. Sharathkumar Amy Shapiro Indiana Hemophilia and Thrombosis Center Indianapolis, U.S.A. Published by the World Federation of Hemophilia (WFH), 1999; revised 2008. © World Federation of Hemophilia, 2008 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s website at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff. -
ADAMTS13 in Arterial Thrombosis
ADAMTS13 in Arterial Thrombosis Tamara Bongers ADAMTS13 in Arterial Thrombosis © 2010 Tamara Bongers, Rotterdam, The Netherlands No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without permission from the author or, when appropriate, from publishers of the publications. ISBN: 978-90-9025798-3 Cover design: Tamara Bongers Layout: Henri Wijnbergen and Tamara Bongers Printing: Ipskamp Drukkers, Enschede ADAMTS13 in Arterial Thrombosis ADAMTS13 in arteriële trombose Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.G. Schmidt en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op donderdag 9 december 2010 om 11:30 uur door Tamara Natascha Bongers geboren te Zevenaar Promotiecommissie Promotor: Prof.dr. F.W.G. Leebeek Overige leden: Prof.dr. M.M.B. Breteler Prof.dr. D.W.J. Dippel Dr. T. Lisman Copromotor: Dr. M.P.M. de Maat The work described in this thesis was performed at the Deparment of Hematology of Erasmus University Medical Center, Rotterdam, The Nether- lands. This work was partly funded by MRACE Translational Research Grant ErasmusMC 2004 as a clinical fellow to F.W.G. Leebeek. Financial support by the Netherlands Heart Foundation for publication of this thesis is gratefully acknowledged. Printing of this thesis was financially supported by Baxter, Erasmus University Rotterdam, Jurriaanse Stichting, Kordia and Pfizer. “ The World is a book, and -
Rare Thrombophilic Conditions
342 Review Article Page 1 of 10 Rare thrombophilic conditions Gian Luca Salvagno1, Chiara Pavan2, Giuseppe Lippi1 1Section of Clinical Biochemistry, University of Verona, Verona, Italy; 2Division of Geriatric Medicine, Mater Salutis Hospital, Legnago, Verona, Italy Contributions: (I) Conception and design: GL Salvagno; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: GL Salvagno, C Pavan; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Prof. Gian Luca Salvagno, MD, PhD. Sezione di Biochimica Clinica, Dipartimento di Neuroscienze, Biomedicina e Movimento, Università degli Studi di Verona, Ospedale Policlinico G.B. Rossi, Piazzale Scuro, 10, 37134 Verona, Italy. Email: [email protected]. Abstract: Thrombophilia, either acquired or inherited, can be defined as a predisposition to developing thromboembolic complications. Since the discovery of antithrombin deficiency in the 1965, many other conditions have been described so far, which have then allowed to currently detect an inherited or acquired predisposition in approximately 60–70% of patients with thromboembolic disorders. These prothrombotic risk factors mainly include qualitative or quantitative defects of endogenous coagulation factor inhibitors, increased concentration or function of clotting proteins, defects in the fibrinolytic system, impaired platelet function, and hyperhomocysteinemia. In this review article, we aim to provide an overview on epidemiologic, clinic and laboratory aspects of both acquired and inherited rare thrombophilic risk factors, especially including dysfibrinogenemia, heparin cofactor II, thrombomodulin, lipoprotein(a), sticky platelet syndrome, plasminogen activator inhibitor-1 apolipoprotein E, tissue factor pathway inhibitor, paroxysmal nocturnal haemoglobinuria and heparin-induced thrombocytopenia.